Multimodal Smoking Cessation in a Real-Life Setting: Combining Motivational Interviewing With Official Therapy and Reduced Risk Products

Background: Tobacco use is a global pandemic, affecting an estimated 1.2 billion people and resulting in substantial health burdens and associated costs. Objectives: The aim of this study was to estimate the efficacy of several treatments for smoking cessation in a real-life setting and to evaluate predictors of smoking abstinence. Methods: This research was designed with a sample of 593 cases recorded over the period between 2015 and 2016. Six treatment groups were included: (1) bupropion and motivational interviewing (MI); (2) bupropion, nicotine replacement therapy (NRT), and MI; (3) NRT and MI; (4) varenicline and MI; (5) personal vaporizer electronic cigarette and MI; and (6) electronic cigarette, cigarette like “cigalike,” and MI. Results: Results support the efficacy of all treatment groups when used in a real-life setting. The predictors of smoking abstinence were sex, partner smoking status, previous quit attempts, daily consumption, self-efficacy, and level of nicotine dependence. Conclusions: The use of different therapeutic strategies in clinical practice, including pharmacotherapy and nonstandard electronic nicotine delivery systems, such as an electronic cigarette, ensures a greater chance of cessation success and the possibility of tailoring interventions according to patients’ resources.

Download Full-text

AB0369 EFFICACY AND SAFETY OF RITUXIMAB ORIGINATOR AND BIOSIMILAR IN PRIMARY SJÖGREN’S SYNDROME IN A REAL-LIFE SETTING

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.6608 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1485.3-1485

Author(s):

F. Carubbi ◽

A. Alunno ◽

P. Cipriani ◽

V. Pavlych ◽

C. DI Muzio ◽

...

Keyword(s):

Disease Activity ◽

Real Life ◽

Primary Sjögren’S Syndrome ◽

Efficacy And Safety ◽

Research Support ◽

Treatment Groups ◽

Real Life Setting ◽

Patient Reported ◽

Time Point

Background:Over the last 2 decades rituximab (RTX) has been widely used, albeit off-label, in primary Sjögren’s syndrome (pSS). Several studies reported that B-lymphocyte depletion with RTX is effective in this disease not only by reducing disease activity but also by affecting the inflammation and the lymphoid organization that occur in target tissues. With the recent release of several RTX biosimilars (bRTX) on the market, the demonstration of their interchangeability with RTX originator (oRTX) is required.Objectives:To compare efficacy and safety of oRTX and bRTX in pSS patients in a real-life setting.Methods:Clinical records of pSS patients referring to a tertiary rheumatology clinic were retrospectively evaluated. Patients having received at least 2 courses of either oRTX or bRTX (1000 mg IV infusion, repeated after 2 weeks -1 course- and the course repeated after 24 weeks) with complete data at baseline and after 3, 6, 9 and 12 months of treatment were enrolled. Disease activity was assessed with the EULAR SS disease activity index (ESSDAI) and its clinical version without the biological domain (ClinESSDAI). Patient-reported symptoms were assessed with the EULAR SS Patient Reported Index (ESSPRI).Results:Seven patients that received oRTX and 7 patients that received bRTX were enrolled. Baseline clinical features, including ESSDAI and ESSPRI were similar in the 2 treatment groups. Both compounds significantly reduced ESSDAI and ESSPRI as early as 3 months and no difference between the groups was observed at any time point (Figure 1). Of interest, ESSDAI slowly decreased until month 6 when the most pronounced reduction was observed. Conversely, ESSPRI dropped to its lowest values already at month 3. With regard to safety, at 12 months of follow-up no adverse event was observed in any of the treatment groups.Conclusion:At 12 months of follow-up, oRTX and bRTX display similar efficacy and safety profiles. The improvement of patient reported outcomes is faster than the improvement of disease activity with both compounds. Our data support interchangeability of oRTX and bRTX in pSS.References:[1]Carubbi F et al. Arthritis Res Ther. 2013;15(5):R172[2]Carubbi F et al. Lupus. 2014;23(13):1337-49Figure 1 ESSDAI and ESSPRI values at every time point in the 2 treatment groups. Asterisks indicate p values <0.05 compared to the other treatment group at the same time pointDisclosure of Interests:Francesco Carubbi Speakers bureau: Francesco Carubbi received speaker honoraria from Abbvie and Celgene outside this work., Alessia Alunno: None declared, Paola Cipriani Grant/research support from: Actelion, Pfizer, Speakers bureau: Actelion, Pfizer, Viktoriya Pavlych: None declared, claudia di muzio: None declared, Roberto Gerli: None declared, Roberto Giacomelli Grant/research support from: Actelion, Pfizer, Speakers bureau: Abbvie, Roche, Actelion, BMS, MSD, Ely Lilly, SOBI, Pfizer

Download Full-text

Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting

BMC Cardiovascular Disorders ◽

10.1186/s12872-015-0180-4 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 5

Author(s):

André Pacheco Silva ◽

Jaqueline Scholz ◽

Tania Ogawa Abe ◽

Gabriela Gouveia Pinheiro ◽

Patricia Viviane Gaya ◽

...

Keyword(s):

Blood Pressure ◽

Cardiovascular Disease ◽

Heart Rate ◽

Smoking Cessation ◽

High Risk ◽

Risk Score ◽

Real Life ◽

Real Life Setting

Download Full-text

Levofloxacin for NIH Category II Chronic Bacterial Prostatitis: A Real-Life Study

Chemotherapy ◽

10.1159/000499034 ◽

2019 ◽

Vol 64 (1) ◽

pp. 8-16 ◽

Cited By ~ 3

Author(s):

Vittorio Magri ◽

Gianpaolo Perletti ◽

Tommaso Cai ◽

Konstantinos Stamatiou ◽

Alberto Trinchieri ◽

...

Keyword(s):

Adverse Effects ◽

Single Agent ◽

Real Life ◽

Symptom Index ◽

Life Study ◽

Treatment Groups ◽

Urogenital Infections ◽

Real Life Setting ◽

Urological Procedures ◽

Clinical Records

Background: Mounting worldwide resistance trends make the use of fluoroquinolone (FQ) antibacterial agents increasingly difficult. This is felt more acutely in the case of urogenital infections, which are mainly caused by Gram-negative pathogens. For years, levofloxacin and other FQs have been the first-line drugs for treating National Institutes of Health (NIH) category II chronic bacteria prostatitis (CBP). Eradication rates achieved by levofloxacin in the frame of randomized trials vary greatly, ranging between 71 and 86%. Objectives: This was a retrospective observational study to investigate the efficacy of levofloxacin against CBP in a real-life setting (urological outpatient wards). Methods: A database including the clinical records of >2,500 CBP patients was reviewed. Patients were selected based on strict inclusion criteria. They were treated for 4 weeks with 500 mg levofloxacin per day, alone or combined with other antibacterials. Besides standard urological procedures including the 4-glass test for pathogen isolation, international symptom questionnaires (the NIH Chronic Prostatitis Symptom Index [NIH-CPSI] and International Prostate Symptom Score [IPSS]) were administered. Results: Pathogen eradication was achieved in 79% of the cases treated with levofloxacin as a single agent and 87.8% of patients who received a combination of levofloxacin and azithromycin. The 11% increase in the eradication rate in the latter group is statistically significant. In addition, the levofloxacin-azithromycin combination caused a significant decrease in prostate volume and significantly increased the bladder-voided volume. IPSS and NIH-CPSI values and the urinary peak flow rate decreased to a similar extent in both treatment groups. No adverse effects were reported by patients belonging to either treatment group. Conclusion: Levofloxacin retained its therapeutic efficacy in patients assessed in a real-life setting, and high eradication rates were attained when it was administered as a single agent. A combination of an FQ with azithromycin induced a significant improvement of eradication rates. This strategy may be an interesting option in both first-referral and relapsing cases, although caution should be exercised when patients are at risk of developing arrhythmias, tendinitis, or other adverse effects.

Download Full-text

The Gold Standard Programme: smoking cessation interventions for disadvantaged smokers are effective in a real-life setting

Tobacco Control ◽

10.1136/tobaccocontrol-2011-050194 ◽

2012 ◽

Vol 22 (6) ◽

pp. e9-e9 ◽

Cited By ~ 12

Author(s):

Tim Neumann ◽

Mette Rasmussen ◽

Nermin Ghith ◽

Berit L Heitmann ◽

Hanne Tønnesen

Keyword(s):

Smoking Cessation ◽

Gold Standard ◽

Real Life ◽

Real Life Setting

Download Full-text

Mobile Social Network–Based Smoking Cessation Intervention for Chinese Male Smokers: Pilot Randomized Controlled Trial

JMIR mhealth and uhealth ◽

10.2196/17522 ◽

2020 ◽

Vol 8 (10) ◽

pp. e17522

Author(s):

Jinsong Chen ◽

Elsie Ho ◽

Yannan Jiang ◽

Robyn Whittaker ◽

Tingzhong Yang ◽

...

Keyword(s):

Smoking Cessation ◽

Social Network ◽

Smoking Status ◽

Intervention Group ◽

Smoking Cessation Intervention ◽

Smoking Abstinence ◽

Mobile Social Network ◽

Motivational Messages ◽

Cessation Intervention ◽

Chinese Male

Background Around 2 million Chinese people, mostly men, die annually from tobacco-related diseases; yet, fewer than 8% of Chinese smokers ever receive any smoking cessation support. Objective This study aimed to test the preliminary effectiveness and feasibility for a mobile social network (WeChat)–based smoking cessation intervention (SCAMPI program) among Chinese male smokers. Methods Chinese male smokers aged 25-44 years were recruited online from WeChat, the most widely used social media platform in China. Individuals using other smoking cessation interventions or who lacked capacity to provide online informed consent were excluded. Participants were randomly assigned (1:1) to intervention or control groups. Neither participants nor researchers were masked to assignment. The trial was fully online. All data were collected via WeChat. The intervention group received access to the full-version SCAMPI program, a Chinese-language smoking cessation program based on the Behaviour Change Wheel framework and relevant cessation guidelines. Specific intervention functions used in the program include: planning to help users make quitting plans, calculator to record quitting benefits, calendar to record progress, gamification to facilitate quitting, information about smoking harms, motivational messages to help users overcome urges, standardized tests for users to assess their levels of nicotine dependence and lung health, as well as a social platform to encourage social support between users. The control group had access to a static WeChat page of contacts for standard smoking cessation care. Both groups received incentive credit payments for participating. The primary outcome was 30-day biochemically verified smoking abstinence at 6 weeks after randomization, with missing data treated as not quitting. Secondary outcomes were other smoking status measures, reduction of cigarette consumption, study feasibility (recruitment and retention rate), and acceptability of and satisfaction with the program. Results The program recorded 5736 visitors over a 13-day recruitment period. We recruited 80 participants who were randomly allocated to two arms (n=40 per arm). At 6 weeks, 36 of 40 (90%) intervention participants and 35 of 40 (88%) control participants provided complete self-reported data on their daily smoking status via WeChat. Biochemically verified smoking abstinence at 6 weeks was determined for 10 of 40 (25%) intervention participants and 2 of 40 (5%) control participants (RR=5, 95% CI 1.2-21.4, P=.03). In the intervention group, the calculator function, motivational messages, and health tests were underused (less than once per week per users). Participants rated their satisfaction with the intervention program as 4.56 out of 5.00. Conclusions Our program is a novel, accessible, and acceptable smoking cessation intervention for Chinese male smokers. A future trial with a greater sample size and longer follow-up will identify if it is as effective as these preliminary data suggest. Trial Registration ANZCTR registry, ACTRN12618001089224; https://tinyurl.com/y536n7sx International Registered Report Identifier (IRRID) RR2-18071

Download Full-text

Mobile Social Network–Based Smoking Cessation Intervention for Chinese Male Smokers: Pilot Randomized Controlled Trial (Preprint)

10.2196/preprints.17522 ◽

2019 ◽

Author(s):

Jinsong Chen ◽

Elsie Ho ◽

Yannan Jiang ◽

Robyn Whittaker ◽

Tingzhong Yang ◽

...

Keyword(s):

Smoking Cessation ◽

Social Network ◽

Smoking Status ◽

Intervention Group ◽

Smoking Cessation Intervention ◽

Smoking Abstinence ◽

Mobile Social Network ◽

Motivational Messages ◽

Cessation Intervention ◽

Chinese Male

BACKGROUND Around 2 million Chinese people, mostly men, die annually from tobacco-related diseases; yet, fewer than 8% of Chinese smokers ever receive any smoking cessation support. OBJECTIVE This study aimed to test the preliminary effectiveness and feasibility for a mobile social network (WeChat)–based smoking cessation intervention (SCAMPI program) among Chinese male smokers. METHODS Chinese male smokers aged 25-44 years were recruited online from WeChat, the most widely used social media platform in China. Individuals using other smoking cessation interventions or who lacked capacity to provide online informed consent were excluded. Participants were randomly assigned (1:1) to intervention or control groups. Neither participants nor researchers were masked to assignment. The trial was fully online. All data were collected via WeChat. The intervention group received access to the full-version SCAMPI program, a Chinese-language smoking cessation program based on the Behaviour Change Wheel framework and relevant cessation guidelines. Specific intervention functions used in the program include: planning to help users make quitting plans, calculator to record quitting benefits, calendar to record progress, gamification to facilitate quitting, information about smoking harms, motivational messages to help users overcome urges, standardized tests for users to assess their levels of nicotine dependence and lung health, as well as a social platform to encourage social support between users. The control group had access to a static WeChat page of contacts for standard smoking cessation care. Both groups received incentive credit payments for participating. The primary outcome was 30-day biochemically verified smoking abstinence at 6 weeks after randomization, with missing data treated as not quitting. Secondary outcomes were other smoking status measures, reduction of cigarette consumption, study feasibility (recruitment and retention rate), and acceptability of and satisfaction with the program. RESULTS The program recorded 5736 visitors over a 13-day recruitment period. We recruited 80 participants who were randomly allocated to two arms (n=40 per arm). At 6 weeks, 36 of 40 (90%) intervention participants and 35 of 40 (88%) control participants provided complete self-reported data on their daily smoking status via WeChat. Biochemically verified smoking abstinence at 6 weeks was determined for 10 of 40 (25%) intervention participants and 2 of 40 (5%) control participants (RR=5, 95% CI 1.2-21.4, <i>P</i>=.03). In the intervention group, the calculator function, motivational messages, and health tests were underused (less than once per week per users). Participants rated their satisfaction with the intervention program as 4.56 out of 5.00. CONCLUSIONS Our program is a novel, accessible, and acceptable smoking cessation intervention for Chinese male smokers. A future trial with a greater sample size and longer follow-up will identify if it is as effective as these preliminary data suggest. CLINICALTRIAL ANZCTR registry, ACTRN12618001089224; https://tinyurl.com/y536n7sx INTERNATIONAL REGISTERED REPORT RR2-18071

Download Full-text

Psychological Factors and Long-Term Abstinence After Smoking Cessation Treatment

The Journal of Smoking Cessation ◽

10.1375/jsc.4.1.10 ◽

2009 ◽

Vol 4 (1) ◽

pp. 10-17 ◽

Cited By ~ 3

Author(s):

Hedwig Boudrez

Keyword(s):

Smoking Cessation ◽

Smoking Status ◽

Statistical Significance ◽

Postal Survey ◽

University Hospital ◽

Smoking Abstinence ◽

Psychological Variables ◽

Smoking Cessation Treatment ◽

Cessation Treatment

AbstractThis study evaluated the association between psychological variables, measured by questionnaire at the start of a smoking cessation treatment, and smoking abstinence, 8 years after treatment. A total of 124 patients presenting at the stop-smoking clinic of the University Hospital in Ghent, Belgium, were included. Besides the Reasons for Smoking Scale (RSS), Fagerstrom Test for Nicotine Dependence (FTND), and smoking status, a psychological questionnaire (NEO PI-R) was presented at baseline. A postal survey after 8 years was executed in order to assess smoking status and smoke-free survival. In 2008, 103/124 answered the postal survey. 66/103 (64.1%) had relapsed. More men then women were smoke-free (46.2% vs. 18.4%; p = .004). Several associations between psychological baseline characteristics and smoking status at follow-up were detected: lower abstinence at follow-up was associated with lower self-discipline (p = .001), lower goal-directedness (p = .03), higher score on symptoms of depression (p = .03), higher anxiety score (p = .01), higher score on the variable shame (p = .02). Some of these associations are confirmed by Kaplan-Meier survival scores that show borderline significance in case of depression (p = .06), statistically significance in case of self-discipline (p = .05) and shame (p = .05) and clear statistical significance in case of anxiety (p = .007). An association between psychological variables at the start of a smoking cessation treatment and smoking abstinence, even after 8 years, can be accepted.

Download Full-text

Electronic cigarettes

BCIT Environmental Public Health Journal ◽

10.47339/ephj.2017.75 ◽

2017 ◽

Author(s):

Spencer Kaspick ◽

BCIT School of Health Sciences, Environmental Health ◽

Helen Heacock

Keyword(s):

Smoking Cessation ◽

Electronic Cigarettes ◽

Smoking Status ◽

Electronic Cigarette ◽

Cigarette Use ◽

Chi Square ◽

Post Secondary ◽

Quit Smoking ◽

Quitting Smoking ◽

Chi Squared

Background: Electronic cigarettes are a widely-used, yet still emerging technology. As such, there is relatively little data regarding the reasons why people take up their use. Many claim to use them as a smoking-cessation method. Concern exists that experimentation in non-smokers may lead to nicotine addiction and subsequent smoking. The purpose of this study was to determine the primary reasons for the commencement of electronic cigarette use, and to suggest way in which these findings could affect current policies and regulations pertaining to electronic cigarettes. Methods: A survey examining electronic cigarette use was prepared. The survey contained questions respecting primary motivation for use, frequency of use, present and former smoking status as well as agreement with common perception about electronic cigarettes. Basic demographic information was also collected. The survey was posted to “www.reddit.com” and was accessible to users who used electronic cigarettes themselves via the “/r/electronic_cigarettes” sub-Reddit for a period of five days. Once responses were collected, Chi-square tests of independence were run to determine if any associations existed. Responses were also compared to previous studies of a similar nature to see if any similarities existed. Results: In total, 155 responses were received. The majority of the respondents were males (89.7%) between the ages of 19 and 28 (47.7%). 30.32% listed their occupation as “student”, and almost three-quarters of the respondents had some post-secondary experience. 78.1% of respondents were former smokers, and 61.3% identified their primary reason for electronic cigarette use as “to quit smoking.” Chi-squared tests for association between responses yielded statistically-significant associations between being a previous smoker and believing that electronic-cigarettes are healthier than conventional cigarettes, and between gender (specifically being male) and reasons for electronic cigarette use (specifically “to quit smoking”). However, the latter result was possibly skewed by a higher response rate from males as opposed to females. Conclusion: The high proportion of previous smokers among electronic cigarette users suggested that quitting smoking was the most common reason individuals take up electronic cigarette usage. It is therefore suggested that studies be done to determine if their use is less harmful than that of conventional cigarettes, and that existing legislation regarding their use in public be modified in light of this evidence. It is also suggested that they be given consideration as a legitimate means of smoking cessation.

Download Full-text

Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial

10.1101/2021.07.03.21259600 ◽

2021 ◽

Author(s):

Stjepan Oreskovic ◽

Jeffrey H. Ashburner ◽

Hrvoje Tiljak ◽

Janez Rifel ◽

Tin Oreskovic ◽

...

Keyword(s):

Primary Care ◽

Smoking Cessation ◽

Care Setting ◽

Primary Care Setting ◽

Controlled Trial ◽

Real Life ◽

Randomized Controlled ◽

Real Life Setting ◽

Care Practices ◽

Primary Care Practices

Our study aims to implement a smoking cessation program using pharmacotherapy in a real-life setting (primary care practices in Croatia and Slovenia) and to investigate whether cytisine is at least as feasible and effective as Varenicline in helping smokers to quit in a randomized non-inferiority trial. The use of these medications as an intervention tool for smoking cessation in Croatia and Slovenia is not previously explored and the level of awareness and interest in pharmacotherapy among smokers is unknown.

Download Full-text